Paclitaxel/Ritonavir

紫杉醇/利托那韦

Report date: 2025/07/17 10:41:48

Base Information

Drug NamePaclitaxel/Ritonavir
Drug Alias NamePaclitaxel+Ritonavir利托那韦/紫杉醇Paclitaxel-Ritonavir紫杉醇+利托那韦Paclitaxel•Ritonavir +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHuman immunodeficiency virus type 1 protease inhibitorsTubulin inhibitors
TargetsHuman immunodeficiency virus type 1 proteaseTubulin
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes PaclitaxelRitonavir
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesModra Pharmaceuticals Bv
China Registration ClassN/A

Develop Information

Active CompaniesThe Netherlands Cancer Institute
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A